Aspiration Pneumonia Management in Patients with Penicillin Allergy

Primary Recommendations

For patients with aspiration pneumonia and penicillin allergy, the American College of Physicians recommends using a respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) as monotherapy for low-risk patients, or combining with an aminoglycoside for high-risk patients, ensuring adequate anaerobic coverage 1

The Infectious Diseases Society of America recommends that patients with low mortality risk and no MRSA risk factors receive levofloxacin 750 mg IV daily as first-line monotherapy 1
For patients with MRSA risk factors, the Society for Healthcare Epidemiology of America recommends levofloxacin 750 mg IV daily or ciprofloxacin 400 mg IV q8h, plus vancomycin 15 mg/kg IV q8-12h or linezolid 600 mg IV q12h 1
The American Thoracic Society recommends that patients with high mortality risk receive dual antipseudomonal coverage, including aztreonam 2 g IV q8h, plus one of the following: levofloxacin 750 mg IV daily, ciprofloxacin 400 mg IV q8h, or an aminoglycoside 2

The Centers for Disease Control and Prevention recommends assessing MRSA risk factors, including prior IV antibiotic use within 90 days, hospitalization in a unit with high MRSA prevalence, and prior MRSA detection by culture or screening 1
The American College of Chest Physicians recommends assessing mortality risk factors, including the need for mechanical ventilation due to pneumonia and the presence of septic shock 1

The European Respiratory Society recommends obtaining appropriate cultures before initiating antibiotics and assessing clinical response at 48-72 hours 1, 3
The Infectious Diseases Society of America recommends de-escalating therapy based on culture results and clinical improvement 1